Telehealth Suboxone laws in Texas 2026: what you need to know

2026 compliance summary: Texas telehealth buprenorphine

Key Takeaways

• It is currently legal in Texas to start Suboxone treatment via telehealth without a prior in-person visit. This is permitted under two overlapping federal frameworks: the Fourth Temporary Extension (through December 31, 2026) and the permanent Expansion of Buprenorphine Treatment via Telemedicine Encounter rule (effective December 31, 2025).
• Texas practitioners must hold a valid Texas medical license and follow Texas Medical Board standards of care. Federal rules open the telehealth pathway; Texas state licensing and standard-of-care requirements still apply.
• Texas requires e-prescribing for all controlled substances. Under HB 2174 (effective January 1, 2021), buprenorphine prescriptions in Texas must be transmitted electronically, with limited exceptions.
• Texas prescribers must check PMP Aware before prescribing. Mandatory PDMP review prior to prescribing opioids and related controlled substances is required under Texas law.
• Audio-only telephone consultations are permitted for buprenorphine OUD treatment under the permanent federal rule. This matters particularly for patients in rural Texas without reliable video access.
• The regulatory landscape is still evolving. The permanent buprenorphine rule requires an in-person visit for prescriptions beyond the initial six-month supply under its own framework, though the broader temporary extension provides additional flexibility through the end of 2026. Check current guidance before assuming ongoing telehealth access after December 31, 2026.

The federal framework: two overlapping rules

Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (through December 31, 2026):

Published December 30, 2025 by the DEA and HHS, this extension continues the pandemic-era flexibility allowing DEA-registered practitioners to prescribe Schedule II-V controlled substances via audio-video telehealth, and Schedule III-V controlled substances approved for OUD treatment via audio-only telehealth, without a prior in-person medical evaluation. This is the broadest current pathway and has the fewest requirements.

Expansion of Buprenorphine Treatment via Telemedicine Encounter (permanent rule, effective December 31, 2025):

This final rule creates a permanent pathway specifically for buprenorphine OUD treatment via telehealth. Key provisions:

• A practitioner may prescribe an initial supply of up to six months of buprenorphine via audio-video or audio-only telehealth without a prior in-person evaluation
• The practitioner must check PDMP data in the state(s) where the patient was located in the prior year before issuing the prescription
• After the initial six-month supply, continued buprenorphine prescribing via telemedicine under this specific rule requires an in-person visit or prescribing through another authorized mechanism

How they interact in 2026:

During 2026, practitioners can use either pathway. Most practitioners are using the temporary extension, which is less restrictive. Patients initiated on buprenorphine during 2026 under the temporary extension are not automatically cut off at six months — the temporary extension covers them through December 31, 2026. What happens after December 31, 2026 depends on whether the DEA finalizes permanent regulations, extends the temporary rule again, or both. This page will be updated as guidance is issued.

Texas-specific requirements

Texas Medical Board standards of care

Texas practitioners providing telehealth services must meet the same standard of care as in-person providers. The Texas Medical Board (TMB) requires a thorough clinical evaluation, including review of the patient's medical history, appropriate clinical assessment, and documented clinical decision-making. A telehealth prescription for buprenorphine is not a shortcut around clinical evaluation — it is a different method of delivering the same evaluation.

Texas also requires telehealth platforms to use HIPAA-compliant technology. The enforcement discretion period for non-HIPAA-compliant video platforms (like FaceTime or Zoom consumer) that existed during the COVID-19 PHE has ended. Providers must use HIPAA-compliant telehealth platforms. Bicycle Health uses a compliant platform for all visits.

Texas PMP Aware (prescription monitoring)

Texas law (Texas Health and Safety Code, effective March 1, 2020) requires prescribers to check PMP Aware, Texas's prescription drug monitoring program, before issuing or dispensing any new or refill prescription for an opioid, benzodiazepine, barbiturate, or carisoprodol.

This requirement applies equally to telehealth prescriptions. Your provider will check PMP Aware before issuing your buprenorphine prescription. This is standard clinical practice that applies regardless of how the visit is conducted.

Texas e-prescribing requirement (HB 2174)

Texas HB 2174 (86th Legislature, 2019), effective January 1, 2021, requires prescriptions for all controlled substances (Schedules II through V) to be transmitted electronically, with limited exceptions including:

• Emergency situations where the patient would face delay that adversely affects their medical condition
• Technological limitations not reasonably within the provider's control
• Other exceptional circumstances with a granted waiver

For standard telehealth buprenorphine prescribing, electronic prescribing is required. Bicycle Health uses secure electronic prescribing, sending prescriptions directly to your pharmacy through a compliant e-prescribing system. No paper prescription is needed.

Pharmacy access in Texas

Texas law does not permit a pharmacist to refuse to fill a valid prescription solely because it was issued via telehealth. A telehealth buprenorphine prescription from a licensed Texas prescriber is legally equivalent to an in-person prescription. Pharmacists retain the right to refuse prescriptions they have clinical or safety concerns about, but telehealth origin is not a valid basis for refusal.

Practical note for Texas patients: buprenorphine/naloxone stock varies by location, particularly in rural areas. Calling your preferred pharmacy to confirm stock before going is advisable. Major chain pharmacies (CVS, Walgreens, HEB Pharmacy, Walmart Pharmacy) generally maintain stock; smaller independent pharmacies in rural areas may need to order it.

Why telehealth matters particularly in Texas

Texas is a geographically large state with significant rural and underserved areas. Access to in-person addiction medicine specialists is highly concentrated in urban centers like Houston, Dallas, San Antonio, and Austin. Patients in West Texas, the Panhandle, the Rio Grande Valley, and rural East Texas often face substantial travel requirements to reach in-person OUD treatment.

Telehealth eliminates this access barrier. A patient in Lubbock, Laredo, or a small Hill Country town can receive the same buprenorphine evaluation and treatment from a licensed Texas provider as someone in Houston, without traveling hours each way.

The audio-only option under the permanent buprenorphine rule also matters in rural Texas, where video connectivity can be limited. Patients without reliable high-speed internet can still access buprenorphine treatment through a phone call with a licensed provider.

Bicycle Health in Texas

Bicycle Health operates in Texas and serves patients across the state via telehealth. Texas providers on the Bicycle Health network hold valid Texas medical licenses and DEA registrations, follow Texas Medical Board standards of care, use HIPAA-compliant platforms, and comply with Texas e-prescribing and PDMP requirements.

Appointments are typically available the same day. Prescriptions are sent electronically to a pharmacy of your choice. Follow-up visits are conducted via video or phone depending on circumstances and patient preference.

See if Bicycle Health is currently accepting patients in your area of Texas.

Frequently Asked Questions

Is it legal to get Suboxone online in Texas in 2026?

Yes. Under the DEA/HHS Fourth Temporary Extension in effect through December 31, 2026, and the permanent Expansion of Buprenorphine Treatment via Telemedicine Encounter rule (effective December 31, 2025), Texas patients can be evaluated and prescribed buprenorphine for opioid use disorder via telehealth without a prior in-person visit. The provider must be licensed in Texas and hold a valid DEA registration.

Does the Texas Medical Board allow telehealth prescribing of Suboxone?

Yes, within the requirements of the standard of care. The Texas Medical Board requires telehealth providers to conduct the same quality of clinical evaluation as in-person providers, use HIPAA-compliant platforms, and comply with all applicable state and federal prescribing requirements. Telehealth prescribing is permitted; the standard is just as rigorous as in-person care.

Do I need to give my provider a urine drug test before starting?

This is a clinical decision made by your provider. Some providers require urine drug screening before or at initiation; others do not. Your provider will discuss the monitoring plan during your evaluation. Texas law requires PDMP check before prescribing but does not mandate a urine drug screen for initiating buprenorphine.

Can I use audio-only (phone) for my Suboxone visits in Texas?

For OUD treatment with buprenorphine, audio-only encounters are permitted under the permanent federal buprenorphine telemedicine rule. This option is specifically valuable for patients in rural areas without reliable video connectivity. Your provider can advise on what your visit type will be.

What happens after December 31, 2026?

The Fourth Temporary Extension covers telehealth buprenorphine prescribing through December 31, 2026. After that date, the permanent buprenorphine rule provides a pathway, but it limits telehealth prescribing to an initial six-month supply before requiring an in-person visit under its own framework. The DEA may issue further extensions or permanent regulations before the end of 2026. This page will be updated as guidance is issued. If you are starting or continuing treatment, discuss the regulatory timeline with your provider.